In vivo profiling for oral candidiasis drug target discovery

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44DE017033-02A1
Agency Tracking Number: DE017033
Amount: $724,482.00
Phase: Phase II
Program: SBIR
Awards Year: 2009
Solicitation Year: 2009
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Small Business Information
GUILD ASSOCIATES, INC.
GUILD ASSOCIATES, INC., 5750 SHIER-RINGS RD, DUBLIN, OH, 43016
DUNS: 001004258
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DAVID SCHOFIELD
 (843) 573-0095
 DSCHOFIELD@GUILDASSOCIATES.COM
Business Contact
 ROBERT FREEBURN
Phone: (614) 798-8215
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Candida albicans is the most frequently isolated fungal pathogen of humans and represents an important public health problem. However, antifungal treatments are hampered by emerging resistance, toxicity concerns, lack of fungicidal activity, and narrow spectrum of action. Thus, there is a critical need for new antifungal drug targets, and new antifungal drug strategies. An important step in the identification of new targets for antifungal drug discovery is the use of in vivo genome profiling using appropriate diseased samples to identify fungal-specific genes which are required for infection. The Phase I application successfully utilized emerging technologies to identify C. albicans genes induced during murine oral candidiasis. Specifically, we identified a subset of: (i) in vivo expressed genes; (ii) infection and colonization-associated genes, and (iii) novel and fungal-specific genes that will likely play a role in the transition from comced targets identified during the Phase I research are required for oral infection. Specific C. albicans knockout strains will be generated and assessed for their ability to cause disease during oral candidiasis. Specific Aim 2 will demonstrate that oligonucleotides can function as antifungal agents against Candida species in vitro. Oligonucleotides will be designed against pre-existing antifungal drug targets and against infection- required targets identified in Specific Aim 1. The oligonucleotides will be preferentially designed against domains within the gene open reading frame that are conserved amongst pathogenic fungi. The antifungal capability of the oligonucleotides will be assessed specifically at the mRNA level, and analyzed for the corresponding alterations in growth, viability, or specific phenotype trait. Specific Aim 3 will demonstrate that the oligonucleotides can be used alone, and in combination with known antifungal agents, to treat murine oral candidiasis. The rese Mucosal candidiasis is the mostcommon type of Candida infection and occurs frequently in immunocompromised patients, and patients with an altered bacterial flora. Despite the large number of at risk patients, antifungal treatment is hampered by toxic side effects and emerging antifungal resistant Candida strains and species.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government